141st APHA Annual Meeting and Exposition

Home Events & Meetings Annual Meeting Schedule & Program

Recorded Annual Meeting Presentations (RAMP) are now available for purchase.
Only $90 for presenters, $140 for registered attendees and $200 for non-attendees.

Online Program

294833
Expanding frontiers in understanding and treating cardiovascular risk in patients treated for cancer: Cardiotoxicity surveillance and potential cardioprotective agents


Tuesday, November 5, 2013 : 1:15 p.m. - 1:30 p.m.

Sinziana Seicean-Boose, MD, MPH, PhD, Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH
     
This review will assess cancer and cardiovascular disease-causing common risk behaviors while focusing on emerging cardiovascular events associated with anticancer therapy. As cardiotoxicity represents a substantial ongoing health burden, clinicians, public health professionals, and policy makers awareness is encouraged for onco-vigilance (pharmacovigilance oriented to oncologic drugs), and also for increasing the collective effort towards future research addressing new cost-effective cardioprotection treatments . Ongoing research conducted at Heart and Vascular Institute, Cleveland Clinic will be used to exemplify current efforts toward better understanding and treatment of cardiotoxicity.

Learning Areas:

Advocacy for health and health education
Basic medical science applied in public health
Chronic disease management and prevention
Clinical medicine applied in public health
Epidemiology
Other professions or practice related to public health

Learning Objectives:
Define treatment–induced cardiotoxicity in cancer survivors including types of cardiotoxic effects, causative chemotherapy agents, and incidence/prevalence range. Describe the public health burden of cardiotoxicity associated with anticancer therapy List Preexisting Cardiovascular Risk in Cancer Survivors Describe the need of clinical practice guidelines for posttreatment monitoring for cardiotoxicity and cardiovascular health in cancer survivors. Identify further research in the area of epidemiology and public health with the goal of improving long-term cardiac outcomes in cancer patients

Keyword(s): Cancer, Public Health Research

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have over a decade of experience in research of epidemiology including conducting and publishing research on cardioprotective agents
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 4212.0: Expanding Frontiers in Understanding Cardiovascular Disease and Diabetes Mellitus Epidemiology and Prevention